1 / 1

Vandetanib(Caprelsa)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

TABLET

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Vandetanib (CAPRELSA) is an oral medication used primarily for the treatment of medullary thyroid cancer (MTC). It acts by inhibiting key receptor tyrosine kinases involved in tumor growth and metastasis, offering a treatment option for patients with advanced and metastatic forms of this cancer. The drug is taken once daily and is available in tablet form with 100 mg and 300 mg strengths. It requires careful dose adjustments for those with renal impairment and may cause severe cardiac or dermatologic side effects .

This manual summarizes the essential clinical information based on the drug's official prescribing information. Please consult healthcare providers for personalized medical advice.

Generic name

Vandetanib(Caprelsa)

English name

Vandetanib

Alternative Names

Caprelsa

Drug prices

Indications

Treatment of symptomatic or progressive medullary thyroid carcinoma (MTC) in adult patients with unresectable locally‑advanced or metastatic disease. Use in indolent/asymptomatic MTC only after weighing treatment‑related risks.

Therapeutic Target

Multi‑kinase inhibition of RET, VEGFR‑2/-3, and EGFR tyrosine‑kinase signaling pathways, resulting in antiproliferative and anti‑angiogenic effects.

Active Ingredients

Vandetanib

Dosage form

TABLET

specifications

Description

Vandetanib is a synthetic anilino‑quinazoline tyrosine‑kinase inhibitor; molecular formula C₂₂H₂₄N₄O₃Cl; acts by selectively blocking RET, VEGFR‑2/-3, EGFR signaling implicated in MTC tumor growth and vascularization.

Dosage and Administration

Standard dose: 300 mg orally once daily, continuously, with or without food.

Renal impairment (CLcr 30–<50 mL/min): start 200 mg daily.

Tablets must not be crushed; may be dispersed in 2 oz water (no other liquids) and swallowed immediately; residue rinsed with 4 oz water.

Dose modification: reduce to 200 mg, then 100 mg for CTCAE ≥ Grade 3 toxicity or QTcF > 500 ms; interrupt for severe events; resume at lower dose once resolved to Grade ≤ 1/QTcF < 450 ms.

Missed dose: omit if <12 h remain until next scheduled dose.

CATEGORY NAVIGATION